Demonstrates enantioselective synthesis of chiral succinimide derivatives using novel thiourea catalysts, implying new avenues in drug discovery.
Chiral succinimide derivatives are privileged scaffolds in bioactive compounds and pharmaceuticals. In this study, a novel class of bifunctional thiourea catalysts derived from isosteviol and a chiral 1,2-diphenylethylenediamine scaffold was synthesized and applied in the enantioselective Michael addition of aldehydes to maleimides. Under optimized conditions in CH₂Cl₂ at room temperature, a broad range of succinimide derivatives were obtained in high yields (82–97%) with excellent enantioselectivities (up to 99% ee). Both enantiomers of the adducts were accessible by switching between the two catalyst configurations. The substrate scope accommodated various N-aryl maleimides bearing electron-donating or electron-withdrawing groups, as well as alicyclic aldehydes. The reaction was scalable to gram level without loss of efficiency. A plausible enamine-based catalytic mechanism involving dual activation by the thiourea moiety is proposed. This protocol represents a significant advancement in the synthesis of chiral succinimides, offering a robust and scalable route to these valuable intermediates for drug discovery and expanding the utility of isosteviol-based organocatalysts.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: